Editorial: Beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics.
Front Psychiatry – April 23, 2025
Source: PubMed Central
Summary
While psilocybin leads psychedelic research, other compounds show remarkable therapeutic promise. Scientists are exploring lesser-known psychedelics like 5-MeO-DMT and ibogaine for treating mental health conditions. Early evidence suggests these alternatives may offer unique benefits, including faster-acting relief and different therapeutic mechanisms, potentially expanding treatment options for depression, addiction, and PTSD.
Abstract
Editorial: Beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics.